131I治疗儿童及青年格雷夫斯病疗效及影响因素分析

来源期刊：广州医药 | 991-996 发布时间：2024-10-22 收稿时间：2025/11/13 18:45:11 阅读量：37

作者：: 唐倩,

钟彝璞,

付钦卿,

袁钦诗,

倪剑,

刘斌,

关键词：: 格雷夫斯病儿童青年 131I 疗效; Graves' disease children and adolescent ¹³¹I" style="padding-right:10px">131I')">¹³¹I outcome

DOI：: 10.3969/j.issn.1000-8535.2024.09.004

收稿时间：: 2023-10-10
修订日期：
接收日期：
引用总数：: 0

目的探讨¹³¹I治疗儿童及青年格雷夫斯病（GD）的疗效及其影响因素。方法回顾性分析2013年—2022年在简阳市人民医院核医学科院接受¹³¹I治疗且年龄≤22岁的儿童及青年GD患者的临床资料。采用个体计算剂量法,每克甲状腺组织的计划用量为80~140 μCi,依据甲状腺吸碘率及甲状腺质量,确定¹³¹I的用量。依据¹³¹I治疗后3~6个月的甲状腺功能指标,进行疗效评价,甲状腺功能恢复正常或发生甲减视为治愈。统计分析治愈组与非治愈组间的临床疾病特征参数,评估可能影响疗效的因素。结果纳入患者71例：男23例、女48例,年龄11~22岁。患儿甲状腺质量4.8~60.0 g,均值22.1 g。¹³¹I的用量在6~24 mCi,均值11.3 mCi。49例（69%）患者获得治愈,22例（31%）未获治愈。单因素分析显示年龄、性别、促甲状腺激素受体抗体的滴度、甲状腺吸碘率、甲状腺质量及¹³¹I用量等,治愈组与非治愈组间比较差异均无统计学意义（均P>0.05）。结论以每克甲状腺组织80~140 μCi的计划用量,确定¹³¹I用量治疗儿童青年GD的疗效可达69%。

1、 SUZUKI N,NOH J Y,YOSHIMURA R,et al.Does age or sex relate to severity or treatment prognosis in Graves' disease[J] .Thyroid,2021,31(9):1409-1415.

2、 BRITO J P,PAYNE S,SINGH OSPINA N,et al.Patterns of use,efficacy,and safety of treatment options for patients with Graves' disease:a nationwide population-based study[J].Thyroid,2020,30(3):357-364.

3、 AZIZI F,AMOUZEGAR A.Management of thyrotoxicosis in children and adolescents:35 years' experience in 304 patients[J].J Pediatr Endocrinol Metab,2018,31(2):159-165.

4、 GARCíA J S,SARMIENTO M P,BELLO J D,et al.Hyperthyroidism in children and adolescents:experience in a university hospital in Colombia[J].Biomedica,2022,42(2):342-354.

5、 GRONICH N,LAVI I,RENNERT G,et al.Cancer risk after radioactive iodine treatment for hyperthyroidism:A cohort study[J].Thyroid,2020,30(2):243-250.

6、 MIZOKAMI T,HAMADA K,MARUTA T,et al.Long-term outcomes of radioiodine therapy for juvenile Graves disease with emphasis on subsequently detected thyroid nodules:A single institution experience from Japan[J].Endocr Pract,2020,26(7):729-737.

7、 CURY A N,MEIRA V T,MONTE O,et al.Clinical experience with radioactive iodine in the treatment of childhood and adolescent Graves' disease[J].Endocr Connect,2012,2(1):32-37.

8、 ESEN ?,BAYRAMO?LU E,Y?LD?Z M,et al.Management of thyrotoxicosis in children and adolescents:A Turkish multi-center experience[J].J Clin Res Pediatr Endocrinol,2019,11(2):164-172.

9、中华医学会核医学分会.¹³¹I治疗格雷夫斯甲亢指南(2021版)[J].中华核医学与分子影像杂志,2021,41(4):242-253.

10、 NAMWONGPROM S,DEJKHAMRON P,UNACHAK K.Success rate of radioactive iodine treatment for children and adolescent with hyperthyroidism[J].J Endocrinol Invest,2021,44(3):541-545.

11、 ROSS D S,BURCH H B,COOPER D S,et al.2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis[J].Thyroid,2016,26(10):1343-1421.

12、 MOOIJ C F,CHEETHAM T D,VERBURG F A,et al.European thyroid association guideline for the management of pediatric Graves' disease[J].Eur Thyroid J,2022,11(1):e210073.

13、 KAPLOWITZ P B,VAIDYANATHAN P.Update on pediatric hyperthyroidism[J].Curr Opin Endocrinol Diabetes Obes,2020,27(1):70-76.

14、 KAPLOWITZ PB,JIANG J,VAIDYANATHAN P.Radioactive iodine therapy for pediatric Graves' disease:A single-center experience over a 10-year period[J].J Pediatr Endocrinol Metab.2020,33(3):383-389.

15、 LUTTERMAN S L,ZWAVELING-SOONAWALA N,VERBERNE H J,et al.The efficacy and short-and long-term side effects of radioactive iodine treatment in pediatric Graves' disease:A systematic review[J].Eur Thyroid J,2021,10(5):353-363.

16、 NIEDZIELA M.Hyperthyroidism in adolescents[J].Endocr Connect.2021,10(11):R279-R292.

17、 XU Y,WANG Y,ZHANG X,et al.Prognostic value of lymph node ratio in children and adolescents with papillary thyroid cancer[J].Clin Endocrinol(Oxf),2021,95(4):649-656.